Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of ChemoCentryx patents

Patents where

Current Assignee

Name

ChemoCentryx

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10035768 C5aR antagonists	Patent 10035768 was granted and assigned to ChemoCentryx on July, 2018 by the United States Patent and Trademark Office.	ChemoCentryx	ChemoCentryx	United States Patent and Trademark Office	10035768	July 31, 2018
‌ US Patent 11207294 Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2	Patent 11207294 was granted and assigned to ChemoCentryx on December, 2021 by the United States Patent and Trademark Office.	ChemoCentryx	ChemoCentryx	United States Patent and Trademark Office	11207294	December 28, 2021
‌ US Patent 8637043 Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof	Patent 8637043 was granted and assigned to ChemoCentryx on January, 2014 by the United States Patent and Trademark Office.		ChemoCentryx	United States Patent and Trademark Office	8637043	January 28, 2014
‌ US Patent 8093247 Heteroaryl sulfonamides and CCR2	Patent 8093247 was granted and assigned to ChemoCentryx on January, 2012 by the United States Patent and Trademark Office.		ChemoCentryx	United States Patent and Trademark Office	8093247	January 10, 2012
‌ US Patent 11020394 Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C—C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies	Patent 11020394 was granted and assigned to ChemoCentryx on June, 2021 by the United States Patent and Trademark Office.	ChemoCentryx	ChemoCentryx	United States Patent and Trademark Office	11020394	June 1, 2021
‌ US Patent 10532051 Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor 9 (CCR9) and anti-α4β7 integrin blocking antibodies	Patent 10532051 was granted and assigned to ChemoCentryx on January, 2020 by the United States Patent and Trademark Office.	ChemoCentryx	ChemoCentryx	United States Patent and Trademark Office	10532051	January 14, 2020
‌ US Patent 11045469 Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies	Patent 11045469 was granted and assigned to ChemoCentryx on June, 2021 by the United States Patent and Trademark Office.	ChemoCentryx	ChemoCentryx	United States Patent and Trademark Office	11045469	June 29, 2021
‌ US Patent 10137120 Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides	Patent 10137120 was granted and assigned to ChemoCentryx on November, 2018 by the United States Patent and Trademark Office.	ChemoCentryx	ChemoCentryx	United States Patent and Trademark Office	10137120	November 27, 2018
‌ US Patent 7435830 Bicyclic and bridged nitrogen heterocycles	Patent 7435830 was granted and assigned to ChemoCentryx on October, 2008 by the United States Patent and Trademark Office.		ChemoCentryx	United States Patent and Trademark Office	7435830	October 14, 2008
‌ US Patent 7435831 Bicyclic and bridged nitrogen heterocycles	Patent 7435831 was granted and assigned to ChemoCentryx on October, 2008 by the United States Patent and Trademark Office.		ChemoCentryx	United States Patent and Trademark Office	7435831	October 14, 2008
‌ US Patent 7442512 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors	Patent 7442512 was granted and assigned to ChemoCentryx on October, 2008 by the United States Patent and Trademark Office.		ChemoCentryx	United States Patent and Trademark Office	7442512	October 28, 2008
‌ US Patent 7572600 Enzymatic activities in chemokine-mediated inflammation	Patent 7572600 was granted and assigned to ChemoCentryx on August, 2009 by the United States Patent and Trademark Office.		ChemoCentryx	United States Patent and Trademark Office	7572600	August 11, 2009
‌ US Patent 11304952 Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor	Patent 11304952 was granted and assigned to ChemoCentryx on April, 2022 by the United States Patent and Trademark Office.	ChemoCentryx	ChemoCentryx	United States Patent and Trademark Office	11304952	April 19, 2022
‌ US Patent 7576106 Piperidine derivatives and methods of use	Patent 7576106 was granted and assigned to ChemoCentryx on August, 2009 by the United States Patent and Trademark Office.		ChemoCentryx	United States Patent and Trademark Office	7576106	August 18, 2009
‌ US Patent 11324736 Method of Treating Focal Segmental Glomerulosclerosis		ChemoCentryx	ChemoCentryx	United States Patent and Trademark Office	11324736	May 10, 2022
‌ US Patent 6939885 Aryl sulfonamides	Patent 6939885 was granted and assigned to ChemoCentryx on September, 2005 by the United States Patent and Trademark Office.		ChemoCentryx	United States Patent and Trademark Office	6939885	September 6, 2005
‌ US Patent 9573897 C5AR antagonists	Patent 9573897 was granted and assigned to ChemoCentryx on February, 2017 by the United States Patent and Trademark Office.	ChemoCentryx	ChemoCentryx	United States Patent and Trademark Office	9573897	February 21, 2017
‌ US Patent 7777035 Azaindazole compounds and methods of use	Patent 7777035 was granted and assigned to ChemoCentryx on August, 2010 by the United States Patent and Trademark Office.		ChemoCentryx	United States Patent and Trademark Office	7777035	August 17, 2010
‌ US Patent 11266643 Triaryl compounds for treatment of PD-L1 diseases	Patent 11266643 was granted and assigned to ChemoCentryx on March, 2022 by the United States Patent and Trademark Office.	ChemoCentryx	ChemoCentryx	United States Patent and Trademark Office	11266643	March 8, 2022
‌ US Patent 10329314 Soluble C5aR antagonists	Patent 10329314 was granted and assigned to ChemoCentryx on June, 2019 by the United States Patent and Trademark Office.	ChemoCentryx	ChemoCentryx	United States Patent and Trademark Office	10329314	June 25, 2019
‌ US Patent 7335653 Bis-aryl sulfonamides	Patent 7335653 was granted and assigned to ChemoCentryx on February, 2008 by the United States Patent and Trademark Office.		ChemoCentryx	United States Patent and Trademark Office	7335653	February 26, 2008
‌ US Patent 9567323 Substituted anilines as CCR(4) antagonists	Patent 9567323 was granted and assigned to ChemoCentryx on February, 2017 by the United States Patent and Trademark Office.	ChemoCentryx	ChemoCentryx	United States Patent and Trademark Office	9567323	February 14, 2017
‌ US Patent 11357760 Method of treating liver fibrosis		ChemoCentryx	ChemoCentryx	United States Patent and Trademark Office	11357760	June 14, 2022
‌ US Patent 7582661 Aryl sulfonamides	Patent 7582661 was granted and assigned to ChemoCentryx on September, 2009 by the United States Patent and Trademark Office.		ChemoCentryx	United States Patent and Trademark Office	7582661	September 1, 2009
‌ US Patent 7622583 Heteroaryl sulfonamides and CCR2	Patent 7622583 was granted and assigned to ChemoCentryx on November, 2009 by the United States Patent and Trademark Office.		ChemoCentryx	United States Patent and Trademark Office	7622583	November 24, 2009

...

Results per page:

174 results

0 selected

174 results

0 selected